Recent studies have also suggested a beneficial role of GLP-1 RAs in the prevention of stroke, MACE, and cardiovascular mortality.23 Consistent with the current post hoc analysis, a recent systematic review that evaluated the composite outcomes of MACE reported that GLP-1 RAs were associated with significant reduction in the relative risk of stroke (as an individual component of MACE; HR, 0.86 [95% CI, 0.77–0.97]; P=0.012).24 Of note, in the current study, the significant stroke benefit was driven by a significant reduction in risk of small vessel occlusion with semaglutide versus placebo. The gene discussed is GLP1R; the disease is stroke disorder.